Alnylam Expands Asian Presence With RNAi License To Japan's GeneDesign
• By PharmAsia News
Alnylam Pharmaceuticals has granted Osaka, Japan-based GeneDesign a nonexclusive license to provide small interfering RNA research products and services using Alnylam's Kreutzer-Limmer patent estate, the companies announced Oct. 3
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
